5PFIZER - Abiomed Europe GmbH
The main goal of the study is to determine biomarkers for patients with non-invasive bladder cancer (NMIBC) after transurethral resection of the bladder tumor, which will allow for precise determination of which NMIBC patients are at high risk of recurrence and require adjuvant treatment. Selecting a group of patients who are likely to benefit most from complementary immunotherapy will contribute to further individualization of oncological treatment, avoiding side effects of therapy and improving the quality of life of patients. In the studies so far, individual, selected elements of the microenvironment have been analyzed, and we would like to comprehensively investigate the tumor microenvironment. Accumulated knowledge about the relationship between cancer cells and the microenvironment will form the basis for further research to learn more about the biology of bladder cancer, which may lead to the development of new diagnostic and therapeutic strategies. The results of the project will certainly have a significant impact on the development of science.